Bruker (NASDAQ:BRKR) Earns Neutral Rating from Bank of America

Bruker (NASDAQ:BRKR)‘s stock had its “neutral” rating restated by investment analysts at Bank of America in a research note issued to investors on Friday, June 21st, MarketBeat.com reports. They currently have a $52.00 price target on the medical research company’s stock, up from their prior price target of $44.00. Bank of America‘s price objective points to a potential upside of 5.78% from the company’s previous close.

A number of other equities analysts have also recently commented on BRKR. Svb Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. BidaskClub raised Zai Lab from a “sell” rating to a “hold” rating in a report on Wednesday, June 5th. Leerink Swann raised Bruker from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Needham & Company LLC cut Acquity Group from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Finally, BTIG Research increased their price target on Bruker to $57.00 and gave the company a “buy” rating in a research note on Friday, June 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Bruker presently has a consensus rating of “Buy” and an average price target of $48.20.

Shares of Bruker stock traded down $0.69 during trading on Friday, reaching $49.16. 1,001,791 shares of the company’s stock were exchanged, compared to its average volume of 646,593. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. Bruker has a 1-year low of $26.10 and a 1-year high of $51.41. The stock has a market cap of $7.82 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.44 and a beta of 1.32. The company has a 50-day simple moving average of $46.52.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. Bruker had a return on equity of 26.28% and a net margin of 9.53%. The company had revenue of $461.40 million during the quarter, compared to analysts’ expectations of $450.46 million. During the same quarter in the previous year, the firm earned $0.24 EPS. Bruker’s revenue was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Bruker will post 1.62 EPS for the current fiscal year.

In other Bruker news, CEO Frank H. Laukien sold 400,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $41.48, for a total value of $16,592,000.00. Following the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Marc A. Kastner sold 1,374 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $41.79, for a total value of $57,419.46. Following the completion of the transaction, the director now owns 10,811 shares in the company, valued at approximately $451,791.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 801,374 shares of company stock worth $33,241,419. 26.50% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the business. O Shaughnessy Asset Management LLC bought a new position in Bruker in the first quarter worth approximately $35,000. Captrust Financial Advisors lifted its holdings in shares of Bruker by 164.7% in the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 1,135 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Bruker in the fourth quarter valued at approximately $176,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Bruker in the fourth quarter valued at approximately $192,000. Finally, ARP Americas LP bought a new position in shares of Bruker in the first quarter valued at approximately $212,000. Institutional investors and hedge funds own 66.73% of the company’s stock.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Story: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.